Vaccitech, a clinical-stage T cell immunotherapy company developing viral vectors as vaccines to treat and prevent cancer and infectious diseases, announces today that it has appointed Mariem Charafeddine as its new chief medical officer.
Mariem brings over 15 years’ experience in the biopharmaceutical industry, spent both advancing the clinical development and commercialisation of infectious disease products, and in delivering post-marketing monitoring of licensed medical products. She has also previously worked in international medical leadership roles and drug development in infectious diseases.
“We are delighted to have Mariem join our team as we advance towards the Phase IIb read-outs of our lead clinical program in influenza,” said Tom Evans, Vaccitech CEO.
He continued, “Her wide-ranging clinical development and post-marketing expertise in infectious diseases also puts us in great stead ahead of first in human studies for our HPV and HBV therapeutics. We look forward to her input on how best to develop our vaccines for the patients that need them.”
By: Anna Smith
Source: Pharma Times
Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.
On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.
General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.